This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Survodutide
Dual GLP-1/Glucagon Receptor Agonist (Oxyntomodulin-Class)
/WHAT_IT_IS
Survodutide (BI 456906) is a long-acting peptide that co-activates GLP-1 and glucagon receptors, designed to deliver robust body-weight reduction by coupling GLP-1–mediated appetite control with glucagon-driven increases in energy expenditure and hepatic lipid mobilization.
/USAGE
Studied for chronic weight management and metabolic disease, including obesity and metabolic dysfunction–associated steatohepatitis (MASH).
/MECHANISM_OF_ACTION
Agonism at GLP-1R enhances glucose-dependent insulin secretion, slows gastric emptying, reduces appetite, and suppresses inappropriate glucagon; concurrent GCGR activation increases energy expenditure and promotes fatty-acid oxidation. The combined signaling can yield greater weight loss than GLP-1–only agonism.
Reported Benefits
- +Clinically meaningful body-weight reduction (once-weekly dosing)
- +Improved glycemic and cardiometabolic markers in study populations
- +Reductions in liver fat and MASH-related biomarkers in trials
- +Potential improvements in waist circumference and lipid parameters
Reported Side Effects
- −Class-typical GI effects (nausea, vomiting, diarrhea/constipation)
- −Decreased appetite
- −Injection-site reactions
- −Possible mild heart-rate increase (glucagon component, dose-dependent)
- −Rare: gallbladder disease or pancreatitis (incretin class consideration)
/STACKED_WITH
/RESEARCH_NOTES
Phase 2 studies reported dose-dependent weight loss and liver-fat reductions; Phase 3 obesity and MASH programs are underway. Monitor GI tolerability, pancreatic enzymes, gallbladder risk, and heart rate due to GCGR activity.
/REFERENCE
https://pubmed.ncbi.nlm.nih.gov/?term=survodutide/RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.